Previous 10 | Next 10 |
United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S....
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 26, 2021 /PRNewswire/ -- United Therapeutics Corporation (...
United Therapeutics (UTHR) has submitted an NDA to the FDA for Tyvaso DPI (inhaled treprostinil) for pulmonary arterial hypertension.United Therapeutics is using a priority review voucher with the application meaning a decision could be rendered by December 2021.In January, the comp...
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indications Priority review voucher applied to the NDA...
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., April 19, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the development of Tyvaso DPI ™ as United Therapeutics submitted a new drug application (NDA) to...
Investors largely shrugged off the most recent earnings report from United Therapeutics (NASDAQ: UTHR) , a pharma company that focuses on pulmonary hypertension. Sometimes, however, past financial results can cloud the vision a company has for its future. The savviest investors ...
Do You Have These Top Health Care Stocks On Your April Watchlist? With the Biden administration rolling out its infrastructure proposal, the American Jobs Plan on Wednesday, things do look promising for health care stocks . You might be asking, how does this relate to health car...
Sonoma Pharmaceuticals (SNOA) +28% on agreement with EMC pharma.Future FinTech Group (FTFT) +24% on acquiring bitcoin mining farm.AeroCentury (ACY) +22%.Jaguar Health (JAGX) +19% on FY results.P&F Industries (PFIN) +21%.AgEagle Aerial Systems (UAVS) +19% on FY results....
The FDA has approved United Therapeutics' (UTHR) Tyvaso (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability.This is the second FDA-approved indication for Tyvaso, which was ...
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with pot...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...